Scinai Immunotherapeutics Ltd. (SCNI) SEC Filings & Earnings Calls

Dilution from equity financings may pressure existing shareholders.

“I recognize the dilution associated with these equity financings.” · word for word

Customer concentration risk; future phases uncommitted and dependent on performance.

“This additional work is uncommitted and excluded from both the $5.1 million base commitment and Committed Customer Orders.” · word for word

Cash runway estimates depend on sales assumptions, customer payments, and execution; subject to termination rights.

“Both estimates depend on achievement of our sales and collection assumptions, timely customer payments and successful execution, and remain subject to customer termination rights” · word for word

Dilution risk from warrants; potential further dilution if warrants exercised; reliance on equity financing for growth.

“Warrants to acquire up to 3,687,501 ADSs at $1.20 per ADS; pre-funded warrants also issued.”

Customer concentration risk; single counterparty for $5.1M contract

“Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company” · word for word

Performance and termination rights could reduce committed revenue

“subject to performance and the agreement’s terms, including applicable termination rights” · word for word

No new financial or operational risks disclosed; compliance risk resolved.

“Filing only addresses Nasdaq compliance; no financial metrics or guidance provided.”

Loss of PC111 program; reliance on CDMO revenue and grant funding for NanoAb.

“no further agreement was reached ... Option Agreement and related License Agreement terminated”

Nasdaq delisting risk due to low bid price; reverse split may not restore compliance.

“There can be no assurance that the ADS Ratio Change will enable the Company to regain or maintain compliance with Nasdaq’s continued-listing requirements.” · word for word

Operating loss widening due to CDMO expansion costs and cost allocation changes may pressure cash runway.

“Operating loss was $2.5 million, compared to $1.6 million in the prior-year period.” · word for word

Revenue decline of 16.6% year-over-year indicates potential top-line weakness.

“Revenues for the three months ended March 31, 2026 were $489 thousand, compared to $586 thousand for the three months ended March 31, 2025.” · word for word

Acquired subsidiary has substantial doubt as a going concern with significant losses and working capital deficit.

“Auditor's report indicates substantial doubt about going concern; loss of NIS 9,395k, working capital deficit NIS 22,819k, equity deficit NIS 51,382k.”

Dilution from issuance of 5.2M ADSs and warrants for additional 5.2M ADSs.

“Issuance of 5,208,333 ADSs and warrants for up to 5,208,333 additional ADSs.”

Low offering price ($0.48 per ADS) indicates distressed financing.

“Purchase price of $0.48 per ADS.” · word for word

Cash runway insufficient

“Our existing cash resources are not sufficient to fund our projected cash requirements at current monthly rates for at least the next 12 months, and we will require significant additional financing in the future to fund our operations.” · word for word

Dependence on additional financing

“We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to any Company product candidate.” · word for word

Clinical development uncertainty

“Due to the inherently unpredictable nature of clinical development processes, we are unable to estimate with any certainty the costs we will incur. Clinical development timelines, the probability of success and development costs can differ materially from expectations.” · word for word

Regulatory and reimbursement risk

“Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit sales of any drug product.” · word for word

Grant approval not guaranteed; timeline and amount uncertain.

“The risk that the FENG grant application is not approved, is approved in a lower amount than anticipated, or is subject to conditions that delay, limit or prevent access to funding” · word for word

Option to acquire PinCell may not be exercised if grant funding not obtained.

“the Company's ability to secure alternative financing required under the option agreement if grant funding is not obtained” · word for word

Potential delisting from Nasdaq if minimum bid price compliance not regained within 180 days.

“received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market’s minimum bid price requirement” · word for word

Dependence on non-dilutive funding and IIA program continuation; potential new IIA program subject to Israel's 2026 state budget approval.

“The Company is monitoring the anticipated launch of a potential new IIA program intended to support industrial CAPEX investments, which would be subject to approval of Israel’s 2026 state budget” · word for word

Integration risk and financial terms not disclosed.

“The financial terms of the Share Purchase Agreement remain confidential.” · word for word

PC111 program at risk due to grant denial; potential termination of option to acquire Pincell.

“On November 24, 2025, Scinai received formal notice from the Polish grant authorities that its €12 million FENG grant application supporting development of PC111 was not approved.” · word for word

Cash runway limited; $3M cash may not sustain operations without additional funding.

“As of September 30, 2025, cash, cash equivalents and short-term deposits totaled $3,005 thousand.” · word for word

Cost-cutting measures indicate financial distress

“Board downsizing and auditor change to reduce cost structure”

Loss of experienced board members

“Two directors resigning, including long-serving members”

Potential dilution from increased authorized shares

“Proposal to increase authorized Ordinary Shares”